IP Library Granted Patent US 12,358,945
Granted Patent B2
US 12,358,945 · App. 15/931,062 · Granted Jul 15, 2025

Methods for purifying antibodies

Inventors: Kent E. Goklen (King of Prussia, PA); Eric J. Suda (Holly Springs, NC); Antonio Raul Ubiera (King of Prussia, PA)
Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
C07K1/22B01D15/3809C07K16/065C07K2317/569
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,358,945
App. No.
15/931,062
Granted
Jul 15, 2025
Kind
B2
Abstract

A method for purifying a protein comprising an antibody, antibody fragment, or immunoglobulin single variable domain, from a solution containing at least one contaminant by superantigen chromatography comprising: a) adsorbing the protein to the superantigen immobilized on a solid support; b) removing the at least one contaminant by contacting the immobilized superantigen containing the adsorbed protein with a first wash buffer comprising an aliphatic carboxylate; and c) eluting the protein from the superantigen immobilized on the solid support.

Claims (33)

1. A method for purifying a protein from a solution by superantigen chromatography comprising:

a) adsorbing the protein to the superantigen immobilized on a solid support;

b) removing at least one contaminant by contacting the immobilized superantigen containing the adsorbed protein with a first wash buffer comprising 50 mM to 125 mM sodium caprylate; and

c) eluting the protein from the superantigen immobilized on the solid support,

wherein the solution comprises the protein and the at least one contaminant,

wherein the solution is a cell culture feed stream, and

wherein the at least one contaminant is selected from the group consisting of a host cell protein and host cell DNA.

2. The method of claim 1 , wherein the first wash buffer comprises 50 mM to 100 mM sodium caprylate.

3. The method of claim 1 , wherein the first wash buffer comprises 50 mM to 75 mM sodium caprylate.

4. The method of claim 1 , wherein the first wash buffer comprises 75 mM to 125 mM sodium caprylate.

5. The method of claim 1 , wherein the first wash buffer comprises 75 mM to 100 mM sodium caprylate.

6. The method of claim 1 , wherein the superantigen is selected from the group consisting of Protein A, Protein G, and Protein L.

7. The method of claim 1 , wherein the wash buffer further comprises 100 mM to 400 mM sodium acetate.

8. The method of claim 1 , wherein the protein is selected from the group consisting of soluble receptor, antibody, antibody fragment, immunoglobulin single variable domain, Fab, F(ab′)2, Fv, disulphide linked Fv, scFv, closed conformation multispecific antibody, disulphide-linked scFv, and diabody.

9. The method of claim 1 , wherein the host cell is selected from the group consisting of E. coli cells, CHO cells, NS0 cells, Sp2/0 cells, COS cells, K562 cells, BHK cells, PER.C6 cells, and HEK cells.

10. The method of claim 1 , wherein the wash buffer further comprises one selected from the group consisting of an organic acid, an alkaline metal salt of the conjugate base of the organic acid, an ammonium salt of the conjugate base of the organic acid, and an organic base.

11. The method of claim 10 , wherein the organic acid is selected from the group consisting of formic acid, acetic acid, lactic acid, citric acid, malic acid, maleic acid, glycine, glycylclycine, succinic acid, TES (2-{[tris(hydroxymethyl)methyl]amino}ethanesulfonic acid), MOPS (3-(N-morpholino)propanesulfonic acid), PIPES (piperazine-N,N′-bis(2-ethanesulfonic acid)), and MES (2-(N-morpholino)ethanesulfonic acid); and wherein the organic base is selected from the group consisting of tris base, Bis-tris, Bis-tris-Propane, Bicine (N,N-bis(2-hydroxyethyl)glycine), HEPES (4-2-hydroxyethyl-1-piperazineethanesulfonic acid), TAPS (3-{[tris(hydroxymethyl)methyl]amino}propanesulfonic acid), and Tricine (N-tris(hydroxymethyl)methylglycine).

12. The method of claim 10 , wherein the conjugate base of the organic acid is one selected from the group consisting of the sodium salt of the conjugate base of the organic acid, the potassium salt of the conjugate base of the organic acid, and the ammonium salt of the conjugate base of the organic acid.

13. A method for purifying a protein from a contaminated solution comprising:

(a) equilibrating Protein A immobilized on a solid phase with Protein A equilibration buffer or equilibrating Protein L immobilized on a solid phase with Protein L equilibration buffer;

(b) adsorbing the protein from the contaminated solution to the Protein A or Protein L immobilized on the solid phase;

(c) removing at least one contaminant by washing the solid phase with a first Protein A or a first Protein L wash buffer comprising 50 mM to 55 mM tris base, 45 mM to 50 mM acetic acid, 50 mM to 125 mM sodium caprylate, and

(d) recovering the protein from the solid phase with a Protein A elution buffer or a Protein L elution buffer,

wherein the contaminated solution comprises the protein and the at least one contaminant,

wherein the contaminated solution is a cell culture feed stream, and

wherein the at least one contaminant is selected from the group consisting of a host cell protein and host cell DNA.

14. The method of claim 13 , further comprising the following step after step (c) and before step (d): removing contaminants by washing the solid phase with a second Protein A wash buffer comprising 55 mM tris base, 45 mM acetic acid, at pH 7.2.

15. The method of claim 13 , further comprising the following steps after step (d): (e) titrating the solution containing the recovered protein to pH 3.0 with 30 mM acetic acid, 100 mM HCl; (f) allowing the solution of step (e) to remain at pH 3.0 for about 30 to 60 minutes; and (g) adjusting the pH of the solution of step (f) to pH 7.5 with 1 M tris.

16. The method of claim 13 , wherein the Protein A wash buffer or the Protein L wash buffer further comprises 1 mM to about 500 mM sodium acetate.

17. The method of claim 13 , wherein the protein is selected from the group consisting of soluble receptor, antibody, antibody fragment, immunoglobulin single variable domain, Fab, F(ab′)2, Fv, disulphide linked Fv, scFv, closed conformation multispecific antibody, disulphide-linked scFv, and diabody.

18. The method of claim 1 , wherein the protein is expressed by the host cell.

19. The method of claim 13 , wherein the protein is expressed by the host cell.

20. The method of claim 15 , further comprising filtering the solution produced by step (g).

Assignments (2)
CHANGE OF ADDRESS Recorded Apr 16, 2025
From: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
Reel/Frame 070854/0469 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2020
From: GOKLEN, KENT E.; SUDA, ERIC J.; UBIERA, ANTONIO RAUL
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED
Reel/Frame 052652/0702 →
Continuity (3)
Continuation 14775868
Provisional Application 61787309 · Mar 15, 2013
Related Publication 20200277330A1 · Sep 3, 2020
References Cited (36)
US 5429746A · Shadle et al. · 1995 [cited by applicant]
US 10259842B2 · Gruber · 2019 [cited by examiner]
US 10676503B2 · Goklen · 2020 [cited by examiner]
US 20030152966A1 · Alred et al. · 2003 [cited by applicant]
US 20080167450A1 · Pan · 2008 [cited by applicant]
US 20080182979A1 · Lihme et al. · 2008 [cited by applicant]
US 20160108084A1 · Gruber et al. · 2016 [cited by applicant]
CN 1922207A · 2007 [cited by applicant]
WO WO03102208A2 · 2003 [cited by applicant]
WO WO2005082937 · 2005 [cited by applicant]
WO WO2005113604A2 · 2005 [cited by applicant]
WO WO2007109163A2 · 2007 [cited by applicant]
WO 2008031020A2 · 2008 [cited by applicant]
WO WO2012135415A1 · 2012 [cited by applicant]
WO 2014141150A1 · 2014 [cited by applicant]
WO 2014186350A1 · 2014 [cited by applicant]
WO 2015038888A1 · 2015 [cited by applicant]
Aboulaich et al., “A Novel Approach to Monitor Clearance of Host Cell Proteins Associated with Monoclonal Antibodies”, Biotechnology Progress, vol. 30, No. 5, pp. 1114-1124 (2014). [cited by applicant]
Chollangi, S. et al., “Development of Robust Antibody Purification by Optimizing Protein-A Chromatography in Combination With Precipitated Methodologies”, Biotechnology and Bioengineering (2015), vol. 112, No. 11, pp. 2… [cited by applicant]
Levy et al., “Development and characterization of a protein A capture step for improved impurity clearance”, Process Development, Biopharmaceutical Development, King of Prussia, PA, Washes—ACS Biot Poster, Denver, 2015,… [cited by applicant]
Li, Heping, “The Production Principle and Technology of Fine Chemicals”, Henan Science and Technology Press, p. 336, Sep. 30, 1994, 4 pages (C1). [cited by applicant]
“Clinical Medical Examination”, Fuzhou Army General Hospital, Shanghai Science and Technology Press, p. 253, Apr. 30, 1978, 7 pages (C2). [cited by applicant]
Brodsky et al., “Caprylic acid precipitation method for impurity reduction: an alternative to conventional chromatography for monoclonal antibody purification”, [cited by applicant]
Chhatre, et al., “Evaluation of a novel agarose-based synthetic ligand adsorbent for the recovery of antibodies from ovine serum”, [cited by applicant]
Monie, Elin, “Evaluation of the 96-well format for screening of chromatographic buffer conditions”, Master's degree project, pp. 1-55 (2006). [cited by applicant]
Newcombe et al., “Optimised affinity purificaiton of polyclonal antibodies from hyper immunised ovine serum using a synthetic Protein A adsorbent, MAbsorbent A2P”, [cited by applicant]
Nilson et al., “Purification of antibodies using protein L-binding framework structures in the light chain variable domain”, [cited by applicant]
Tong et al., “Caprylate as the albumin-selective modifier to improve IgG purification with hydrophobic charge-induction chromatography”, [cited by applicant]
Naik et al., “Performance of Hexamer Peptide Ligands for Affinity Purification of Immunoglobulin G from Commercial Cell Culture Media,” Journal of Chromatography A, vol. 1218, (2011), pp. 1691-1700. [cited by applicant]
Anonymous: “Albumin in Cell Culture,” Sigma-Aldrich, Oct. 26, 2008, pp. 1-2, XP055751730. [cited by applicant]
Chhatre S., et al., “Purification of Antibodies Using the Synthetic Affinity Ligand Absorbent MAbsorbent A2P,” Nature Protocols, 2007, vol. 2(7), pp. 1763-1769. [cited by applicant]
Fraser J.D., et al., “The Bacterial Superantigen and Superantigen-like Proteins,” Immunological Reviews, Oct. 2008, vol. 225, pp. 226-243. [cited by applicant]
Haiou Y., et al., “Purification of Human Immunoglobulin G via Fc-specific Small Peptide Ligand Affinity Chromatography,” Journal of chromatography, Feb. 2009, vol. 1216(6), pp. 910-918. [cited by applicant]
Henry K.A., et al., “A Rational Engineering Strategy for Designing Protein a-binding Camelid Single-domain Antibodies,” PLos One, Sep. 2016, vol. 11(9), pp. 1-18. [cited by applicant]
Le Merdy S., “Selection of Clarification Methods for Improved Downstream Performance and Economics,” Bioprocessing Journal, Oct. 2015, vol. 14(3), pp. 50-55. [cited by applicant]
Liu Z., et al., “Effects of Peptide Density and Elution pH on Affinity Chromatographic Purification of Human Immunoglobulins A and M,” Journal of Chromatography A, Nov. 2011, vol. 1218(46), pp. 8344-8352. [cited by applicant]
Cited By (1)
US 12,686,702